BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, ...
(Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, and provides updates on its antiviral product pipeline ... in the U.S.
Genital herpes, usually caused by herpes simplex virus type 2 (HSV-2), is the most common cause of genital ... Management includes antiviral drug therapy--acyclovir, valacyclovir, or famciclovir ...
Four antiviral drugs are available for the prevention and treatment of influenza infections: oseltamivir, zanamivir, rimantadine and amantadine. Oseltamivir and zanamivir are neuraminidase ...